company background image
DNA

Ginkgo Bioworks Holdings NYSE:DNA Stock Report

Last Price

US$2.43

Market Cap

US$4.3b

7D

2.1%

1Y

-75.4%

Updated

16 May, 2022

Data

Company Financials +
DNA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

DNA Stock Overview

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming.

Ginkgo Bioworks Holdings Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Ginkgo Bioworks Holdings
Historical stock prices
Current Share PriceUS$2.43
52 Week HighUS$15.86
52 Week LowUS$2.09
Beta0
1 Month Change-36.72%
3 Month Change-56.22%
1 Year Change-75.43%
3 Year Changen/a
5 Year Changen/a
Change since IPO-75.99%

Recent News & Updates

Apr 01
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Just Reported, And Analysts Assigned A US$10.14 Price Target

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Just Reported, And Analysts Assigned A US$10.14 Price Target

Investors in Ginkgo Bioworks Holdings, Inc. ( NYSE:DNA ) had a good week, as its shares rose 8.3% to close at US$4.03...

Shareholder Returns

DNAUS ChemicalsUS Market
7D2.1%2.1%0.7%
1Y-75.4%-6.4%-10.8%

Return vs Industry: DNA underperformed the US Chemicals industry which returned -6.2% over the past year.

Return vs Market: DNA underperformed the US Market which returned -10.4% over the past year.

Price Volatility

Is DNA's price volatile compared to industry and market?
DNA volatility
DNA Average Weekly Movement15.9%
Chemicals Industry Average Movement7.2%
Market Average Movement7.8%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market2.9%

Stable Share Price: DNA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: DNA's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2008641Jason Kellyhttps://www.ginkgobioworks.com

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.

Ginkgo Bioworks Holdings Fundamentals Summary

How do Ginkgo Bioworks Holdings's earnings and revenue compare to its market cap?
DNA fundamental statistics
Market CapUS$4.31b
Earnings (TTM)-US$1.83b
Revenue (TTM)US$313.84m

13.7x

P/S Ratio

-2.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
DNA income statement (TTM)
RevenueUS$313.84m
Cost of RevenueUS$129.69m
Gross ProfitUS$184.15m
Other ExpensesUS$2.01b
Earnings-US$1.83b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

May 16, 2022

Earnings per share (EPS)-1.03
Gross Margin58.68%
Net Profit Margin-583.12%
Debt/Equity Ratio0%

How did DNA perform over the long term?

See historical performance and comparison

Valuation

Is Ginkgo Bioworks Holdings undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


2.86x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate DNA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate DNA's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: DNA is unprofitable, so we can't compare its PE Ratio to the US Chemicals industry average.

PE vs Market: DNA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate DNA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DNA is overvalued based on its PB Ratio (2.9x) compared to the US Chemicals industry average (2.1x).


Future Growth

How is Ginkgo Bioworks Holdings forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


68.7%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DNA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: DNA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: DNA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: DNA's revenue (27.3% per year) is forecast to grow faster than the US market (8% per year).

High Growth Revenue: DNA's revenue (27.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: DNA is forecast to be unprofitable in 3 years.


Past Performance

How has Ginkgo Bioworks Holdings performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-1,345.4%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: DNA is currently unprofitable.

Growing Profit Margin: DNA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if DNA's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare DNA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DNA is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (34.5%).


Return on Equity

High ROE: DNA has a negative Return on Equity (-117.18%), as it is currently unprofitable.


Financial Health

How is Ginkgo Bioworks Holdings's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: DNA's short term assets ($1.7B) exceed its short term liabilities ($134.8M).

Long Term Liabilities: DNA's short term assets ($1.7B) exceed its long term liabilities ($368.9M).


Debt to Equity History and Analysis

Debt Level: DNA is debt free.

Reducing Debt: DNA has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DNA has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: DNA has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 51.3% each year


Dividend

What is Ginkgo Bioworks Holdings's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate DNA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DNA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DNA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DNA's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as DNA has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.6yrs

Average management tenure


CEO

Jason Kelly (40 yo)

no data

Tenure

US$380,742,276

Compensation

Dr. Jason Kelly serves as Director of Genomatica, Inc. Dr. Kelly Founded Ginkgo Bioworks, Inc. (nka:Ginkgo Bioworks Holdings, Inc.) since 2008 and serves as its Chief Executive Officer and has served as Di...


CEO Compensation Analysis

Compensation vs Market: Jason's total compensation ($USD380.74M) is above average for companies of similar size in the US market ($USD6.90M).

Compensation vs Earnings: Jason's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: DNA's management team is considered experienced (4.6 years average tenure).


Board Members

Experienced Board: DNA's board of directors are considered experienced (4.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.


Top Shareholders

Company Information

Ginkgo Bioworks Holdings, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Ginkgo Bioworks Holdings, Inc.
  • Ticker: DNA
  • Exchange: NYSE
  • Founded: 2008
  • Industry: Specialty Chemicals
  • Sector: Materials
  • Implied Market Cap: US$4.313b
  • Shares outstanding: 1.77b
  • Website: https://www.ginkgobioworks.com

Number of Employees


Location

  • Ginkgo Bioworks Holdings, Inc.
  • 27 Drydock Avenue
  • 8th Floor
  • Boston
  • Massachusetts
  • 2210
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/16 00:00
End of Day Share Price2022/05/16 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.